Radiology

How to Predict Long-Term Infliximab Failure in Crohn's

Published on Nov 16, 2026
3 min read
How to Predict Long-Term Infliximab Failure in Crohn's - OC Academy Medical Insights
"A validated clinical-radiological nomogram accurately predicts loss of response to infliximab in Crohn's disease, guiding timely therapeutic intervention."

Biologic therapy has transformed inflammatory bowel disease management. However, optimizing infliximab in Crohn's disease remains challenging because many patients eventually lose clinical response. Secondary loss of response often leads to disease flare-ups, bowel damage, and surgery. Therefore, clinicians urgently need reliable prediction tools to guide timely decision-making.

Predicting Loss of Response to Infliximab in Crohn's Disease

A recent retrospective observational study evaluated 165 patients receiving regular infliximab therapy. Specifically, the researchers sought to predict loss of response within 78 weeks. They categorized outcomes into uncomplicated and complicated treatment failure. In addition, the team examined baseline characteristics, postinduction laboratory tests, and computed tomography enterography findings. They analyzed 112 patients in the training cohort and 53 in the validation cohort. Consequently, the investigators developed a comprehensive clinical-radiological nomogram.

Key Independent Predictors Identified by LASSO Regression

The team applied LASSO-logistic regression to select candidate predictors. Through this analysis, they identified two independent predictors of long-term failure. First, erythrocyte sedimentation rate at week 14 strongly predicted treatment failure. Second, maximum small bowel wall thickness at baseline was a major predictor. Furthermore, the model achieved remarkable discriminatory power. The nomogram demonstrated an area under the curve of 0.834 in the training cohort. Moreover, the area under the curve reached 0.913 in the validation cohort. The model also predicted uncomplicated failure with an area under the curve of 0.746. Meanwhile, it predicted complicated failure with an area under the curve of 0.876.

Clinical Implications for Practice

The researchers identified critical cut-off values for everyday clinical practice. For instance, postinduction erythrocyte sedimentation rate above 10.5 mm/h indicated shorter response duration. Similarly, a baseline small bowel wall thickness above 7.5 mm predicted early loss of response. Therefore, combining these simple biomarkers helps risk-stratify patients early during maintenance therapy. In fact, clinicians can identify individuals who face complicated structural failure. As a result, gastroenterologists can proactively optimize dosing or switch biologic classes before irreversible bowel complications arise.

Frequently Asked Questions

Q1: What are the primary predictors in this infliximab nomogram?

The nomogram uses two independent predictors: week-14 postinduction erythrocyte sedimentation rate and baseline maximum small bowel wall thickness on imaging.

Q2: What cut-off values signal a high risk of infliximab failure?

Patients with a week-14 erythrocyte sedimentation rate exceeding 10.5 mm/h or baseline bowel thickness exceeding 7.5 mm experience shorter response duration.

Q3: How does this model aid clinical decision-making?

It allows clinicians to identify patients at risk of complicated failure early. Consequently, doctors can proactively adjust therapy before bowel damage occurs.

References

  1. Shi X et al. A nomogram integrating clinical and radiological data to predict long-term infliximab efficacy in Crohn's disease. Eur Radiol. 2026 Nov 15. doi: 10.1007/s00330-026-13068-4. PMID: 43034256.
  2. Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341-353. doi: 10.1016/S2468-1253(19)30012-3.
  3. Chen M, et al. Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study. Gastroenterol Rep (Oxf). 2021;9(3):235-243. doi: 10.1093/gastro/goaa069.

Related Articles You May Like